Project Grant R01AG094919
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded The Johns Hopkins University a $480,710 Project Grant effective September 5, 2025, through May 31, 2030, under the Aging Research program (CFDA 93.866). This research project investigates a novel vascular pathway that regulates neuronal survival in neurodegenerative diseases, including Alzheimer's disease and related dementias (ADRD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). The project...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $1.08 million Project Grant to The Johns Hopkins University on August 1, 2025, under the Aging Research program (CFDA 93.866) to develop adeno-associated virus (AAV) vectors for selective manipulation of oligodendrocyte precursor cells (OPCs). The two-year project, concluding July 31, 2027, will generate novel OPC-selective AAV vectors and utilize them to investigate whether reactive transformation of OPCs surrounding...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Johns Hopkins University a Project Grant (R21) totaling $232,938 on February 17, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award supports research investigating neuronal membrane proteasome-derived peptide (NMP-peptide) signaling in the peripheral nervous system, with performance scheduled through January 31,...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded University of Maryland, Baltimore a Project Grant of $649,766 under the Aging Research program (CFDA 93.866) effective March 1, 2026, with a completion date of January 31, 2031. This research project investigates the role of hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels in olfactory dysfunction associated with aging and neurological diseases, particularly Alzheimer's disease. The project...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Columbia University's Health Sciences Division a Project Grant of $450,200 under the Aging Research program (CFDA 93.866) effective May 15, 2026, with completion targeted for April 30, 2028. This exploratory R21 research grant supports a systematic investigation of age-dependent changes in primary sensory neurons and nociceptors, specifically examining how normal aging remodels peripheral sensory neurons housed...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of South Florida $3.297 million under the Aging Research program (CFDA 93.866) for a four-year project period (September 1, 2025 – August 31, 2029) to develop novel peptidomimetic biomaterials that inhibit amyloid-beta (Aβ42) aggregation in Alzheimer's disease. The research deliverables include the rational design and characterization of structurally related analogues to a lead compound that stabilizes Aβ...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant of $1,459,072 on August 1, 2025, under the Aging Research program (CFDA 93.866) to conduct research on Alzheimer's Disease (AD)-related neurological dysfunction. The research will deliver scientific knowledge and methodological innovations focused on understanding how inhibitory interneurons—specifically parvalbumin (PVALB) and somatostatin (SST) cell types—contribute...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded The Salk Institute for Biological Studies a Project Grant of $620,441 under the Aging Research program (CFDA 93.866), with an award date of February 15, 2026 and ultimate completion date of January 31, 2031. This research initiative focuses on characterizing activity-dependent changes to neuronal populations in the spinal dorsal horn during aging and determining the functional consequences of dorsal horn remodeling for...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $388,750 to the University of Maryland, Baltimore on August 15, 2025, under the Aging Research program (CFDA 93.866) to conduct a large-scale retrospective cohort study examining the association of peripheral nerve blocks (PNBs) with postoperative outcomes and hospital readmissions in older adults undergoing hip fracture surgery. The research project, scheduled for completion by July 31, 2027, will leverage the...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded The Johns Hopkins University $650,872 on August 15, 2025, under the Aging Research program (CFDA 93.866) to investigate bioenergetic and physiological mechanisms underlying slow gait speed and high energetic cost of walking in older adults. Through this project grant, extending to April 30, 2030, Johns Hopkins will conduct baseline and two-year longitudinal assessments of 100 diverse older participants aged 70...
The National Institute on Aging (NIA) awarded The Johns Hopkins University a $597,350 Project Grant (CFDA 93.866 – Aging Research program) effective May 15, 2026, through January 31, 2031, to develop an oral Glutamate Carboxypeptidase II (GCPII) inhibitor therapeutic for peripheral nerve injury in aging populations. The research addresses a critical clinical gap: peripheral nerve regeneration capacity declines significantly with age, leading to prolonged functional impairments in older adults. The project will optimize the prototype GCPII inhibitor 2-PMPA through pharmacological development to improve oral bioavailability and tissue penetration, elucidate the mechanistic pathways by which GCPII inhibition enhances nerve regeneration, and characterize GCPII expression dynamics in human peripheral nerve injury samples across age and sex variables—all essential data for advancing the therapeutic candidate toward clinical translation. This interdisciplinary research initiative leverages Johns Hopkins' established expertise in preclinical peripheral nerve injury models and clinical treatment of peripheral nerve injury patients to bridge fundamental mechanistic understanding with clinical applicability. Preliminary evidence demonstrates that GCPII inhibition significantly enhances remyelination and functional recovery in aged mice following peripheral nerve injury, establishing a promising foundation for human therapeutic development in this underserved aging population.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $597.4k | 5/18/26 |